Angitia Biopharmaceuticals: Funding, Investors & Team (Sep 2026)
Angitia Biopharmaceuticals develops clinical-stage biologic therapies aimed at addressing serious musculoskeletal diseases through scientific research and regulatory-guided trials. The company studies product candidates such as AGA2118 for bone density issues, AGA2115 for connective tissue disorders, and AGA111 for bone fusion, advancing each through controlled clinical development. It operates a pipeline that integrates biologic drug research with data from human and preclinical studies to support regulatory progression and therapeutic evaluation. Angitia Biopharmaceuticals engages with medical and scientific communities to share clinical data and refine development strategies. The organization focuses on drug discovery and development processes that respond to defined clinical needs in musculoskeletal health.
Angitia Biopharmaceuticals has raised $130M across 1 funding round on record, the most recent a Series D of $130M announced in Feb 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Angitia Biopharmaceuticals Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Angitia Biopharmaceuticals Funding Rounds
Angitia Biopharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
Angitia Biopharmaceuticals Funding Compared to Other Biotechnology Startups
Angitia Biopharmaceuticals' latest round of $130M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Angitia Biopharmaceuticals in Biotechnology and Westlake Village
Companies Similar to Angitia Biopharmaceuticals
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Angitia Biopharmaceuticals Funding FAQs
What does Angitia Biopharmaceuticals do?
Angitia Biopharmaceuticals develops clinical-stage biologic therapies aimed at addressing serious musculoskeletal diseases through scientific research and regulatory-guided trials. The company studies product candidates such as AGA2118 for bone density issues, AGA2115 for connective tissue disorders, and AGA111 for bone fusion, advancing each through controlled clinical development. It operates a pipeline that integrates biologic drug research with data from human and preclinical studies to support regulatory progression and therapeutic evaluation. Angitia Biopharmaceuticals engages with medical and scientific communities to share clinical data and refine development strategies. The organization focuses on drug discovery and development processes that respond to defined clinical needs in musculoskeletal health.
How much funding has Angitia Biopharmaceuticals raised?
Angitia Biopharmaceuticals has raised $130M across 1 round on record. The most recent is a Series D of $130M announced in Feb 2026.
When did Angitia Biopharmaceuticals last raise funding?
Angitia Biopharmaceuticals' most recent funding round on record is a Series D of $130M, announced in Feb 2026.
Who founded Angitia Biopharmaceuticals?
FundedIQ lists Hua Zhu Ke (Founder) at Angitia Biopharmaceuticals.
Where is Angitia Biopharmaceuticals headquartered?
Angitia Biopharmaceuticals is based in Westlake Village, California, United States.
How many employees does Angitia Biopharmaceuticals have?
Angitia Biopharmaceuticals is in the 51-100 employee band.
How does Angitia Biopharmaceuticals' funding compare to other Biotechnology startups?
Angitia Biopharmaceuticals' latest round of $130M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Angitia Biopharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Angitia Biopharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.